- Home
- CFBK vs GALT Comparison
CFBK vs GALT Comparison
Compare CFBK & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFBK
- GALT
- Stock Information
- Founded
- CFBK 1892
- GALT 2000
- Country
- CFBK United States
- GALT United States
- Employees
- CFBK N/A
- GALT N/A
- Industry
- CFBK Major Banks
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- CFBK Finance
- GALT Health Care
- Exchange
- CFBK Nasdaq
- GALT Nasdaq
- Market Cap
- CFBK 177.5M
- GALT 147.8M
- IPO Year
- CFBK 1998
- GALT N/A
- Fundamental
- Price
- CFBK $25.58
- GALT $1.04
- Analyst Decision
- CFBK
- GALT Strong Buy
- Analyst Count
- CFBK 0
- GALT 1
- Target Price
- CFBK N/A
- GALT $11.00
- AVG Volume (30 Days)
- CFBK 24.7K
- GALT 1.1M
- Earning Date
- CFBK 02-05-2025
- GALT 11-13-2024
- Dividend Yield
- CFBK 1.09%
- GALT N/A
- EPS Growth
- CFBK N/A
- GALT N/A
- EPS
- CFBK 2.04
- GALT N/A
- Revenue
- CFBK $44,396,000.00
- GALT N/A
- Revenue This Year
- CFBK N/A
- GALT N/A
- Revenue Next Year
- CFBK N/A
- GALT N/A
- P/E Ratio
- CFBK $12.51
- GALT N/A
- Revenue Growth
- CFBK N/A
- GALT N/A
- 52 Week Low
- CFBK $16.92
- GALT $0.73
- 52 Week High
- CFBK $31.17
- GALT $4.27
- Technical
- Relative Strength Index (RSI)
- CFBK 42.63
- GALT 20.80
- Support Level
- CFBK $23.92
- GALT $1.80
- Resistance Level
- CFBK $28.75
- GALT $2.36
- Average True Range (ATR)
- CFBK 1.02
- GALT 0.27
- MACD
- CFBK -0.47
- GALT -0.08
- Stochastic Oscillator
- CFBK 29.70
- GALT 15.07
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans, and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.